Myomics currently performs fee-for-screening services to numerous clients, as well as screening available chemical compound banks in-house for lead compounds for applications in muscular dystrophy, cancer cachexia, sarcopenia, and sports medicine.
Duchenne Muscular Dystrophy
Screening Service for Muscular Dystrophies
• Jett Foundation
• Charley's Fund
• Compound Quest
• Children's National Medical Center
• Validus Biopharma
• Ryan's Quest
• Cure Muscular Dystrophy (CMD)
• PPMD
• Charley's Fund
• Compound Quest
• Children's National Medical Center
• Validus Biopharma
• Ryan's Quest
• Cure Muscular Dystrophy (CMD)
• PPMD
Screening Service for Cancer Cachexia
• Novartis Pharma AG
Screening Service for Academic Centers
• MGH
• Univ. Notre Dame
• Innovation Park- South Bend
• Univ. Central Florida
• Univ. Colorado
• Univ. Notre Dame
• Innovation Park- South Bend
• Univ. Central Florida
• Univ. Colorado
Screening In-House
Myomics In-House Development
The MFAS™ has identified unique compounds beneficial in both Duchenne muscular dystrophy and sports medicine. The first clinical trial is expected to begin in 2010.
Discovery
Preclinical
Clinical
Duchenne Muscular Dystrophy
Sports Medicine/
Supplements
Supplements
Cardiovascular
Sarcopenia
Cancer Cachexia
